Semax: A Literature Course in Six Modules

This course organises the peer-reviewed record on Semax into six modules: what the compound is, how its mechanism is described, what individual studies measured and reported, what adverse or safety-relevant observations appear in print, what pharmacokinetic data exist, and how the compound is classified by regulators. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision. Nothing here is a protocol, a recommendation, or a statement that any reported effect transfers to humans.

One framing note before Module 1. Search phrases such as "N-Acetyl Semax benefits" describe a consumer vocabulary, not a literature vocabulary. The published papers cited below use the names Semax, ACTH(4-7)-PGP and ACTG(4-7)-PGP, and they report endpoints in animals and cells rather than benefits in people. This course keeps the literature's language.

Module 1: What Semax Is and How It Has Been Studied

Semax is a short synthetic peptide built from a fragment of adrenocorticotropic hormone. Researchers described it as an ACTH(4-10) analogue with nootropic properties when they examined its effect on rodent brain monoamine systems (PMID 16362768). In other papers the same molecule is written structurally as ACTH(4-7)-PGP, reflecting the ACTH fragment joined to the tripeptide Pro-Gly-Pro; this notation appears, for example, in a rat transcriptome study of cerebral ischaemia-reperfusion (PMID 32580520) and in a study of hepatocyte morphology under chronic stress, where it was written ACTG(4-7)-PGP (PMID 28577097).

Class. Semax belongs to a family of regulatory peptides derived from pituitary hormone fragments. Its C-terminal Pro-Gly-Pro tail was itself studied as a separate entity: one paper compared Semax with Pro-Gly-Pro on neurotrophin and neurotrophin-receptor gene transcription after cerebral ischemia (PMID 19633950). That comparison is one of the few places where the literature separates the ACTH-derived portion from the proline-rich tail.

Forms and the "N-Acetyl" question. The heavily searched term "N-Acetyl Semax" refers to an acetylated modification of the parent sequence. The verified literature used in this course does not contain a dedicated pharmacology paper on an N-acetylated version under that consumer name. The closest published reference is a 2025 paper in which researchers tested Semax and a derivative of it for effects on pathological impairments in an animal model of Alzheimer's disease (PMID 41479572). Readers encountering marketing claims that attach findings about Semax to an acetylated or amidated analogue should note that the published outcome data in this set were generated with Semax as described by the study authors, not with a consumer-labelled variant.

How it has been studied. The research base is dominated by rodent models of brain injury and stress, plus molecular and in-vitro work. Represented designs include experimental ischemic cortical infarction (PMID 17603664), 6-OHDA-induced Parkinson-like parkinsonism (PMID 28702721), heavy-metal exposure with learning and memory endpoints (PMID 27411820), immobilization stress with coagulation endpoints (PMID 21113455), and a functional connectomic analysis of Semax and Selank (PMID 32342318).

Limits of the evidence — Module 1

Definitions in the literature are consistent, but nomenclature is not: the same peptide appears under at least three written forms, which makes database searching unreliable. The verified set contains no head-to-head pharmacology of acetylated analogues against the parent peptide, so equivalence between "N-Acetyl Semax" and the studied compound is unestablished here.

Module 2: Mechanism as Described in the Literature

Mechanistic papers on Semax cluster into four descriptions. None of them is a complete pharmacological account, and the authors generally present them as candidate pathways rather than settled explanations.

Neurotrophin gene transcription

In a rat model of cerebral ischemia, researchers reported that Semax and Pro-Gly-Pro activated transcription of neurotrophins and their receptor genes (PMID 19633950). This is the most frequently repeated mechanistic claim in secondary writing about the peptide, and it originates from measured transcript changes in injured brain tissue rather than from behavioural inference.

Broader transcriptome effects after ischaemia-reperfusion

A 2020 Genes paper examined protective properties of ACTH(4-7)PGP at the transcriptome level following cerebral ischaemia-reperfusion in rats, reporting changes in gene-expression profiles in brain tissue (PMID 32580520). Transcriptome-wide designs describe which gene groups shift; they do not by themselves demonstrate that a shift caused a clinical or functional outcome.

Monoamine systems

Researchers reported that Semax, described as an ACTH(4-10) analogue with nootropic properties, activated dopaminergic and serotoninergic brain systems in rodents (PMID 16362768). This neurochemical framing is often used to explain behavioural findings in the Parkinson-like and memory models discussed in Module 3.

Metal binding and redox chemistry

A 2025 bioinorganic chemistry paper characterised Semax as a copper chelator peptide and reported that it decreased Cu(II)-catalysed reactive oxygen species production and the cytotoxicity of amyloid-beta through metal ion stripping and redox silencing (PMID 40496623). This is a chemical and cell-level mechanism, distinct from the gene-expression work.

Network-level description

A functional connectomic approach was applied to studying Selank and Semax effects, describing changes at the level of brain network connectivity rather than single receptors (PMID 32342318).

Limits of the evidence — Module 2

No identified high-affinity receptor for Semax appears in this verified set, and the four mechanistic descriptions are not integrated into one model. Gene-expression and connectomic findings are correlative with respect to behaviour. The copper-chelation work was chemical and cellular, so it does not establish that the same chemistry occurs at physiological exposures in a living brain.

Module 3: Reported Outcomes, Study by Study

The table below summarises what each verified paper modelled, what it measured, and what the authors reported. The wording follows the published titles and abstracts. Nothing in this module is a statement that a similar outcome would occur in humans.

Read as a group, these papers describe a peptide studied mainly as an experimental neuroprotective and behaviour-modifying agent in injury models, not as a general-purpose cognitive product. The memory-related findings were generated under a specific insult — cortical infarction (PMID 17603664) or heavy-metal exposure (PMID 27411820) — rather than in healthy, unstressed subjects performing at baseline.

Limits of the evidence — Module 3

The verified set contains no randomised controlled trial in humans. Sample sizes, blinding and randomisation details are not reproduced here and vary across the underlying papers. Animal injury models frequently fail to predict human clinical outcomes, and several endpoints (transcript counts, network metrics, hepatocyte morphology) are intermediate measures rather than patient-relevant outcomes. Reported effects in a lesioned animal cannot be read as expected effects in an uninjured person.

Module 4: Semax Side Effects: What Studies Report

This is the module where the literature is thinnest, and saying so plainly is more useful than filling the gap. None of the verified papers in this course is a toxicology study, a tolerability trial, or a safety-monitoring report with an adverse-event table. What exists instead are physiological observations that are safety-relevant when read carefully.

• Hemostasis. Researchers reported anticoagulation and antiplatelet effects of semax in rats under conditions of acute and chronic immobilization stress (PMID 21113455). The authors framed this as a functional effect on clotting and platelet activity; effects on coagulation are, in general, the kind of pharmacology that clinicians monitor, and this paper is the clearest safety-adjacent signal in the set.
• Liver tissue. A separate rat study examined the influence of ACTG(4-7)-PGP on the morphofunctional state of hepatocytes during chronic emotional and painful stress (PMID 28577097). That design asked directly whether liver cell structure and function changed, which places hepatic tissue among the organ systems that have at least been looked at.
• Central nervous system activity. Reported activation of dopaminergic and serotoninergic brain systems in rodents (PMID 16362768) and reported behavioural changes in lesioned rats (PMID 28702721) indicate that the peptide was neuroactive in these models. Neuroactivity is not the same as an adverse event, but it defines the systems where unintended effects would be expected to appear if they occurred.

Popular write-ups sometimes list specific complaints — irritation, headache, sleep disruption, mood change — attributed to intranasal use. Those lists are not traceable to the verified papers used in this course, so this page does not repeat them as findings.

Limits of the evidence — Module 4

No dose-ranging toxicity data, no long-term exposure study, no human tolerability dataset and no drug-interaction analysis appear in this verified set. The absence of reported adverse events in mechanistic animal papers is not evidence of safety; those studies were not designed to detect or count harms. Anyone assessing risk would need primary safety literature and clinical input, not the papers summarised above.

Module 5: Pharmacokinetics Where Data Exist

Honest answer: within this verified set, they largely do not. None of the cited papers reported plasma concentration curves, half-life, clearance, volume of distribution, absolute bioavailability, metabolite identification or brain-to-plasma ratios for Semax in humans. Because this course cites only verified papers and does not paraphrase numbers it cannot source, no pharmacokinetic parameters are stated here.

Two indirect points can be drawn. First, the peptide's structure is itself a pharmacokinetic argument in the literature: the Pro-Gly-Pro tail was studied as a separate active entity alongside Semax in ischemic rat brain (PMID 19633950), and proline-rich termini are widely discussed in peptide chemistry as stability-influencing motifs. Second, centrally measured outcomes — gene expression in brain tissue after ischaemia-reperfusion (PMID 32580520) and rodent brain monoamine activation (PMID 16362768) — imply that some centrally relevant exposure occurred in those specific experimental conditions, without quantifying it.

Limits of the evidence — Module 5

Inferring exposure from downstream effects is not pharmacokinetics. Without measured concentrations, nothing can be said about equivalence between routes, between species, or between the parent peptide and acetylated analogues. Claims about duration of action or administration frequency circulating in consumer material have no support in this verified set.

Module 6: Regulatory Status, Stated Factually

Regulatory status differs sharply by jurisdiction, and conflating jurisdictions is the most common factual error in Semax content.

1. Russia. Semax was developed at Russian research institutes and is registered there as a pharmaceutical product, which is why the peptide appears in the Russian-language and Russian-affiliated journal literature far more than elsewhere. Several of the papers cited in this course were published in Russian academy journals such as Doklady Biological Sciences and the Bulletin of Experimental Biology and Medicine (PMID 32342318, PMID 17603664).
2. United States. Semax has not been approved by the FDA as a drug and is not an approved dietary ingredient. Material offered in the United States is typically labelled research-use-only (RUO), meaning it is intended for laboratory investigation and is not manufactured, tested or labelled as a medicine for human administration.
3. Compounding. Compounded preparations in the United States must be built from substances that meet specific statutory criteria; peptides lacking an approved product or an entry on the relevant FDA bulk-substances list fall outside routine compounding eligibility, and FDA has treated a number of research peptides accordingly.
4. Sport. Athletes governed by anti-doping codes should note that peptide hormones and related substances are addressed by those codes independently of national drug approval status; the authoritative source is the current prohibited list of the relevant governing body.

This section describes regulatory categories as published by authorities and is not legal advice; regulations change and vary by country and state.

Limits of the evidence — Module 6

Approval in one country is not evidence of efficacy or safety under another regulator's standards, and RUO labelling carries no assurance of identity, purity or sterility. Regulatory classification and scientific evidence are separate questions and should not be used to argue for one another.

What the Studies Did Not Test

A closing inventory of absences, which is often the most decision-relevant part of a literature review:

• Healthy human cognition. The memory-related findings in this set came from rats under cortical infarction (PMID 17603664) or heavy-metal insult (PMID 27411820), not from healthy people tested on validated cognitive batteries.
• The acetylated variant by name. No verified paper here reports outcomes for a consumer-labelled N-Acetyl Semax; the 2025 Alzheimer's-model paper studied Semax and a derivative as defined by its authors (PMID 41479572).
• Long-term exposure. No multi-year or lifetime administration study appears in this set.
• Interactions. Given reported anticoagulation and antiplatelet effects in stressed rats (PMID 21113455), interaction questions with other agents affecting hemostasis are obvious — and unanswered here.
• Special populations. Pregnancy, lactation, paediatric, hepatic and renal impairment populations are not represented.
• Dose-response in humans. No human dose-finding data are present, which is why this course states no dose.

Readers who want to go further should retrieve the primary papers below and read the methods sections, where model details, administration routes and statistical handling are specified by the original authors. Again, this page is educational only and is not medical advice; a licensed physician is the appropriate source for individual health questions.

References

• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease (Acta Naturae, 2025)
• Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia (Cellular and Molecular Neurobiology, 2010)
• Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress (Bulletin of Experimental Biology and Medicine, 2010)
• Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex (Bulletin of Experimental Biology and Medicine, 2006)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats (Genes, 2020)
• Semax prevents learning and memory inhibition by heavy metals (Doklady Biological Sciences, 2016)
• Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (Neurochemical Research, 2005)
• Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of Aβ by Metal Ion Stripping and Redox Silencing (Bioinorganic Chemistry and Applications, 2025)